For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union ...

TransCode Therapeutics ( (RNAZ)) just unveiled an update. On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of Functional Biomaterials of preclinical data showing ...

Investment Rating: BUYRisk Profile: Speculative/ High RIskFirst Price Target (12-months): $25Current Price = $11.05Upside: 127%Tenax Therapeutics (TENX) represents a uniquely positioned investment ...

TG Therapeutics, Inc. (TGTX) is becoming a prominent player in the multiple sclerosis therapeutics market thanks to its Briumvi [ublituximab], an anti-CD20 monoclonal antibody. To my surprise, its ...

TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Intellia Therapeutics, Inc. before investing. In this article, we go over a few ...

BioMarin BMRN-0.16%decrease; red down pointing triangle Pharmaceutical has struck a deal to buy fellow biotech Amicus Therapeutics FOLD 0.10%increase; green up pointing triangle for about $4.8 billion ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology Lead program ST-905, a potent M1/M4 muscarinic agonist, currently ...